Provided by Tiger Trade Technology Pte. Ltd.

MannKind

2.47
-0.0500-1.98%
Post-market: 2.500.0256+1.04%19:43 EDT
Volume:19.09M
Turnover:47.27M
Market Cap:758.46M
PE:123.50
High:2.54
Open:2.54
Low:2.41
Close:2.52
52wk High:6.51
52wk Low:2.41
Shares:307.07M
Float Shares:300.98M
Volume Ratio:4.29
T/O Rate:6.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0200
EPS(LYR):0.0200
ROE:32.74%
ROA:4.91%
PB:-14.87
PE(LYR):123.50

Loading ...

MannKind Reports Record Q4 Revenue and Highlights 2026 Growth Drivers

Reuters
·
Jan 08

Press Release: MannKind Provides Business Updates and 2026 Growth Drivers

Dow Jones
·
Jan 08

MannKind Corporation Secures Five New U.S. Patents for FUROSCIX ReadyFlow Autoinjector

Reuters
·
Dec 23, 2025

MannKind Shares FUROSCIX® Business Updates

GlobeNewswire
·
Dec 23, 2025

MannKind CEO Michael Castagna Reports Disposal of Common Shares

Reuters
·
Dec 17, 2025

MannKind Corporation Issues Amendment on scPharmaceuticals Acquisition Filing

Reuters
·
Dec 16, 2025

MannKind (MNKD): Evaluating Valuation After FDA Acceptance of the FUROSCIX ReadyFlow Autoinjector sNDA

Simply Wall St.
·
Dec 15, 2025

MannKind Corp : Leerink Partners Raises Target Price to $9 From $7

THOMSON REUTERS
·
Dec 09, 2025

MannKind CEO Michael Castagna Reports Disposal of Common Shares

Reuters
·
Dec 05, 2025

BRIEF-Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application (SNDA) Of Furoscix Readyflow™ Autoinjector

Reuters
·
Dec 01, 2025

MannKind Corp - Pdufa Target Action Date Set for July 26, 2026

THOMSON REUTERS
·
Dec 01, 2025

MannKind Announces U.S. FDA Accepts for Review Its Supplemental New Drug Application (Snda) of Furoscix Readyflow™ Autoinjector for the Treatment of Edema in Adults With Chronic Heart Failure or Chronic Kidney Disease

THOMSON REUTERS
·
Dec 01, 2025

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

GlobeNewswire
·
Dec 01, 2025

MannKind (MNKD) Is Up 6.4% After Wave of Analyst Upgrades Despite MNKD-101 Discontinuation – Has The Bull Case Changed?

Simply Wall St.
·
Nov 29, 2025

MannKind Initiated at Buy by Truist Securities

Dow Jones
·
Nov 25, 2025

What MannKind (MNKD)'s Phase 3 Trial Discontinuation Means for Pipeline Prospects and Shareholder Expectations

Simply Wall St.
·
Nov 19, 2025

MannKind (MNKD): Evaluating Valuation as Biotech Sector Dynamics Shift

Simply Wall St.
·
Nov 18, 2025

MannKind EVP Technical Operations Sanjay R. Singh Reports Sale of Common Shares

Reuters
·
Nov 15, 2025

MannKind to Present at the Jefferies Global Healthcare Conference

GlobeNewswire
·
Nov 12, 2025

MannKind Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Nov 11, 2025